---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000822"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:22:16.550237+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Edgewise Therapeutics reports Q1 2023 net loss of $22.8M; cash at $328M; advancing EDG-5506 and EDG-7500 trials

## Summary
- Net loss of $22.8M ($0.36 per share) vs $19.4M in prior quarter; R&D spend rose to $19.9M.
- Cash, cash equivalents and marketable securities of $328M as of March 31, 2023.
- Advancing Phase 2 CANYON (BMD) and LYNX (DMD) trials for EDG-5506; interim DMD data expected Q4 2023.
- IND-enabling studies for EDG-7500 (HCM) ongoing; Phase 1 start expected in 2H2023.
- Plan to add registration-enabling cohort in CANYON in 2H2023; 12-month ARCH data expected Q2 2023.

## SEC filing metadata
- accession: 0001157523-23-000822
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000115752323000822/0001157523-23-000822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000115752323000822/a53398173.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000822
- JSON: https://secwatch.observer/filing/0001157523-23-000822.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000822.txt

## Key facts
- Earnings Releases
  Edgewise Therapeutics, Inc. reported financial results for first quarter of 2023.
  - Period: first quarter of 2023
  - Result: reported results
  source text: Edgewise Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710072/000115752323000822/0001157523-23-000822-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.